1. Scrip
  2. >>Business

Bayer/Versant Launch New Stem Cell Company With Massive Cash Injection

 
• By Sukaina Virji

German giant Bayer has teamed up with investment firm Versant Ventures to launch a new stem cell company with $225m in start-up funding.

New company BlueRock Therapeutics, funded by $225m of series A cash from Bayer AG and Versant Ventures, is based on a new stem cell platform and will have an initial focus on cardiovascular diseases and neurodegenerative disorders.

The stem cell platform at BlueRock has been assembled through a series of partnerships with academic and industry collaborators in the US, Canada and Japan

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Industry Makes Its Case To Trump In Effort To Sidestep Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a 232 investigation.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

Stock Watch: Market Optimism Outshines Q1 Currency And Tariff Woes

 
• By Andy Smith

The weak US dollar helped some companies reporting first-quarter results and hindered others reporting in stronger currencies. But even the impacts of currencies and Medicare modernization on first-quarter revenues were overlooked when an end to the trade wars seemed possible.